Difference between revisions of "Team:TAS Taipei"
| Line 256: | Line 256: | ||
<br> | <br> | ||
<br> | <br> | ||
| − | <div class="row center-block" style = "padding:10px;width:960px;background-color:#07BEB8;box-shadow:0px 0px 5px black"> | + | <!--Title--> |
| + | <div class="row center-block" style = "padding:10px;width:960px;background-color:#07BEB8;box-shadow:0px 0px 5px black"> | ||
<div class="row" style = "text-align:center;"> | <div class="row" style = "text-align:center;"> | ||
| − | + | <div class="col-sm-2"> | |
| − | + | <a href="https://2017.igem.org/Team:TAS_Taipei" style='text-decoration: none'><img src= "https://static.igem.org/mediawiki/2015/2/2f/Tas_igemlogo.png" alt="Tas iGEM Logo" style="width: 100px;"></a> | |
| − | " alt="" style="width: 100px;"></a> | + | </div> <!--TAS iGEM logo--> |
| − | + | <div class="col-sm-8" style='text-align:center;'> | |
| − | + | <a href="https://2017.igem.org/Team:TAS_Taipei" style='text-decoration: none;'> | |
| − | + | <h2 style="font-family:'Lato';letter-spacing:10px;color: white; font-size: 60px; margin-top: 0; margin-bottom: 0;"> | |
| − | + | <b>NANOTRAP</b> | |
| − | + | </h2> | |
| − | + | </a> | |
| − | + | </div> <!--Project Name--> | |
| − | + | <div class="col-sm-2"> | |
| − | + | <a href="https://igem.org/HS"><img src="https://static.igem.org/mediawiki/2016/6/6e/T--TAS_Taipei--TAS_Icon_Logo2.png" alt="" style="width: 100px;"></a> | |
| − | + | </div> <!--iGEM logo--> | |
| − | + | </div> | |
| − | </div> | + | </div> |
| − | + | <!--End of Title--> | |
| − | + | <br> | |
| − | + | ||
| − | + | <!--Slides--> | |
| + | <div id="slider1_container" style="position: relative; top: 0px; left: 6%; width: 1080px; height: 600px;"> | ||
<!-- Loading Screen --> | <!-- Loading Screen --> | ||
<div u="loading" style="position: absolute; top: 0px; left: 0px;"> | <div u="loading" style="position: absolute; top: 0px; left: 0px;"> | ||
| Line 290: | Line 292: | ||
<div u="slides" style="cursor: move; position: absolute; left: 0px; top: 0px; width: 1080px; height: 600px; | <div u="slides" style="cursor: move; position: absolute; left: 0px; top: 0px; width: 1080px; height: 600px; | ||
overflow: hidden;"> | overflow: hidden;"> | ||
| − | <div><div u="image" id="image1ani" style = "lightgrey;text-align:center"><image src="https://static.igem.org/mediawiki/2016/b/bb/T--TAS_Taipei--TeamPhoto_iGEMPoster.jpg"/></div> | + | <div> |
| + | <div u="image" id="image1ani" style = "lightgrey;text-align:center"><image src="https://static.igem.org/mediawiki/2016/b/bb/T--TAS_Taipei--TeamPhoto_iGEMPoster.jpg"/></div> | ||
<div u="caption" t="B" style="box-shadow: 0 0 10px 0;background-color:orange;padding:20px;position: absolute; bottom: 10px; left: 300px;"> | <div u="caption" t="B" style="box-shadow: 0 0 10px 0;background-color:orange;padding:20px;position: absolute; bottom: 10px; left: 300px;"> | ||
| − | |||
<p style = "color:white;font-size:25px;text-align:center"> | <p style = "color:white;font-size:25px;text-align:center"> | ||
<b>BEST MODEL, PARTS COLLECTION,</b> | <b>BEST MODEL, PARTS COLLECTION,</b> | ||
| Line 305: | Line 307: | ||
</div> | </div> | ||
<div><img u="image" src="https://static.igem.org/mediawiki/2016/c/cb/T--TAS_Taipei--Counteract_Homepage_Banner.jpg"/></div> | <div><img u="image" src="https://static.igem.org/mediawiki/2016/c/cb/T--TAS_Taipei--Counteract_Homepage_Banner.jpg"/></div> | ||
| − | <div><div u="image" id="image1ani" style = "lightgrey;text-align:center"><image src="https://static.igem.org/mediawiki/2016/4/41/T--TAS_Taipei--PurificationAnimation.gif"/></div> | + | <div> |
| + | <div u="image" id="image1ani" style = "lightgrey;text-align:center"><image src="https://static.igem.org/mediawiki/2016/4/41/T--TAS_Taipei--PurificationAnimation.gif"/></div> | ||
<div u="caption" t="L" style="box-shadow: 0 0 10px 0;background-color:orange;padding:20px;position: absolute; top: 250px; left: 20px;"> | <div u="caption" t="L" style="box-shadow: 0 0 10px 0;background-color:orange;padding:20px;position: absolute; top: 250px; left: 20px;"> | ||
<p style = "color:white;font-size:32px;"> | <p style = "color:white;font-size:32px;"> | ||
| Line 315: | Line 318: | ||
</div> | </div> | ||
</div> | </div> | ||
| − | <div><div u="image" id="justintime" style = "text-align:center"><image src="https://static.igem.org/mediawiki/2016/4/4e/T--TAS_Taipei--NPAnimation.gif" id="image2ani" /></div> | + | <div> |
| + | <div u="image" id="justintime" style = "text-align:center"> | ||
| + | <image src="https://static.igem.org/mediawiki/2016/4/4e/T--TAS_Taipei--NPAnimation.gif" id="image2ani" /> | ||
| + | </div> | ||
<div u="caption" t="L" style="box-shadow: 0 0 10px 0;background-color:orange;padding:20px;position: absolute; top: 35px; left: 30px;"> | <div u="caption" t="L" style="box-shadow: 0 0 10px 0;background-color:orange;padding:20px;position: absolute; top: 35px; left: 30px;"> | ||
<p style = "color:white;font-size:32px;"> | <p style = "color:white;font-size:32px;"> | ||
| Line 326: | Line 332: | ||
</div> | </div> | ||
<div> | <div> | ||
| − | + | <div u="image" style = "text-align:center;width:10%"> | |
| − | + | <image src="https://static.igem.org/mediawiki/2017/5/58/T--TAS_Taipei--TeamPhoto.jpg"/> | |
| − | + | </div> | |
| − | + | <div u="caption" t="T" style="box-shadow: 0 0 10px 0;background-color:purple;padding:10px;position: absolute; top: 30px; left: 120px;border-style:solid;border-color:gold;border-width:10px"> | |
| − | + | <p style = "color:white;font-size:30px;"> | |
| − | + | <b>TAS Taipei: 2017 iGEM Team</b> | |
| − | + | </p> | |
| − | + | ||
| − | + | ||
</div> | </div> | ||
</div> | </div> | ||
| Line 376: | Line 380: | ||
<a style="display: none" href="http://www.jssor.com">Image Slider</a> | <a style="display: none" href="http://www.jssor.com">Image Slider</a> | ||
</div> | </div> | ||
| + | <!--End of Slides--> | ||
<br> | <br> | ||
<br> | <br> | ||
Revision as of 07:25, 15 May 2017
ABSTRACT
Cataracts, the clouding of the lens, cause half of the world's blindness. Most cataracts are age-related and arise when crystallin proteins in the lens become oxidized and aggregate over time. Surgery is currently the only recognized treatment to effectively cure cataracts, but this method is expensive and invasive. Therefore, we formulated a natural and non-invasive alternative. In the eye, a natural antioxidant glutathione (GSH)—produced by the enzyme glutathione reductase (GSR)—exists to combat oxidation, but GSH levels decrease with age. Studies have also suggested that another enzyme—25-hydroxylase (CH25H)—can convert cholesterol in the eye into 25-hydroxycholesterol (25HC), which reverses crystallin aggregation. We expressed and purified GSR and CH25H for the prevention and treatment of cataracts, respectively. To deliver these proteins through the cornea and into the lens, we engineered biodegradable chitosan nanoparticles, thus creating a natural and non-invasive alternative to surgery.
